http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 08 Jan 2026 09:00:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Jan. 8, 2026</chron></span> /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, <person>John Friend</person>, MD, will be in <location value="LU/us.ca.sanfrn" idsrc="xmltag.org" >San Francisco</location> next week to participate in meetings during the annual <span value="ACORN:6001200803" idsrc="xmltag.org" >J.P. Morgan Healthcare Conference</span> week (JPM Week).</p> <p>During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach.</p><p>"We are entering JPM Week with strong strategic and clinical momentum," said Dr. <person>John http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+to+Participate+in+J.P.+Morgan+Healthcare+Conference+Week%3B+Clinical+and+Translational+Update+Anticipated+Before+Month-End/25824143.html Thu, 08 Jan 2026 09:00:00 +0000 A.60012008 KZA KZIA O.00673961 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987 http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Nov. 18, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span> (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests http://www.streetinsider.com/PRNewswire/Kazia+Therapeutics+Achieves+Initial+iCR+%28Immune-Complete+Response%29+in+Metastatic+TNBC+and+Delivers+Q4+Business+Update+with+Breakthroughs+Across+Breast+Cancer%2C+Immuno-Oncology%2C+and+GBM+Regulatory+Strat/25632115.html Tue, 18 Nov 2025 16:15:00 +0000 A.06822034 A.11670441 A.40151759 A.50200218 A.50205311 KZA KZIA O.00050368 O.00414167 O.00673961 O.15540159 O.20026344 O.47050987